LAB Standard BioTools Inc

Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced the introduction of new solutions that add automation and flexibility to the Imaging Mass Cytometry™ workflow on the Hyperion XTi™ Imaging System.

Spatial biology is vital to clinical and translational research, providing critical insights into disease progression, the identification of biomarkers, drug development and monitoring therapeutic response. Increased adoption of multiplexed tissue imaging as a spatial biology tool is driving a need for higher sample throughput. Standard BioTools™ has developed new groundbreaking capabilities to image tissue samples at never-before-seen speeds and automation, accelerating and deepening insight generation.

Hyperion™ XTi now offers three modes for rapid and detailed spatial biology analysis: (1) Preview Mode for quick whole slide overviews; (2) Tissue Mode for whole slide imaging in real time; and (3) Cell Mode to analyze regions of interest at single-cell resolution. Novel whole slide imaging using Imaging Mass Cytometry (IMC™) offers a unique opportunity to garner the most data out of limited samples with up to 10 times higher throughput than cyclic immunofluorescent imaging. By leveraging the different modes on Hyperion XTi, researchers can quickly visualize tissue heterogeneity in minutes, without having to manage time-consuming cycles, and can then conduct deeper analysis on targeted regions.

In addition, to facilitate high-throughput tissue imaging and accelerate time to results, Standard BioTools has launched a new automated slide loader that can be installed directly on Hyperion XTi for automatic loading and acquisition of up to 40 slides. This walk-away automation option eliminates manual error, reduces hands-on time and enables standardization with barcoded slide identification and LIMS connectivity.

“The innovations we are putting forth demonstrate our commitment to providing the best, most reliable and essential tools for our customers,” said Michael Egholm, PhD, President and CEO of Standard BioTools. “These new capabilities further facilitate the use of IMC across any phase of research, helping establish the technology as an unrivaled leader in spatial proteomics. Now researchers can capture all markers simultaneously in a single scan and generate confident data from 40-plus protein markers on 40 slides in 24 hours, with a fully optimized end-to-end workflow.”

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq:LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, is driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply: www.standardbio.com/legal/salesterms. Patent and License Information: www.standardbio.com/legal/notices. Trademarks: www.standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the potential benefits of a streamlined capitalization structure; our ability to attract new long-term investors and potential M&A partners; future business performance; expectations and operational and strategic plans; deployment of capital; and market and growth opportunities. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, but not limited to, the outcome of any legal proceedings related to the merger with SomaLogic Inc.; risks that the anticipated benefits of the merger with SomaLogic Inc. or other commercial opportunities may otherwise not be fully realized or may take longer to realize than expected; risks that we may not realize expected cost savings from our restructuring, including the anticipated decrease in operational expenses, at the levels we expect; possible restructuring and transition-related disruption, including through the loss of customers, suppliers and employees and adverse impacts on our development activities and results of operation; restructuring activities, including our subleasing plans, customer and employee relations, management distraction and reduced operating performance; risks that internal and external costs required for ongoing and planned activities may be higher than expected, which may cause us to use cash more quickly than we expect or change or curtail some of our plans, or both; risks that our expectations as to expenses, cash usage and cash needs may prove not to be correct for other reasons such as changes in plans or actual events being different than our assumptions; changes in our business or external market conditions; challenges inherent in developing, manufacturing, launching, marketing and selling new products; interruptions or delays in the supply of components or materials for, or manufacturing of, our products; reliance on sales of capital equipment for a significant proportion of revenues in each quarter; seasonal variations in customer operations; unanticipated increases in costs or expenses; continued or sustained budgetary, inflationary or recessionary pressures; uncertainties in contractual relationships; reductions in research and development spending or changes in budget priorities by customers; uncertainties relating to our research and development activities, and distribution plans and capabilities; potential product performance and quality issues; risks associated with international operations; intellectual property risks; and competition. For information regarding other related risks, see the “Risk Factors” section of our annual report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 1, 2024, and in our other filings with the SEC. These forward-looking statements speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements except as may be required by law.

Contacts

Investors

David HolmesGilmartin Group LLCir@standardbio.com

Media

Nick Lamplough/Dan Moore/Tali EpsteinCollected Strategieslab-cs@collectedstrategies.com